• 1. Cinnolines. Part II. Reaction with hydrogen peroxide and acetic acid
  M. H. Palmer,E. R. R. Russell J. Chem. Soc. C 1968 2621

Recent Advances in the Study of 4-Methyl-8-nitroquinoline (CAS: 2801-29-8): A Comprehensive Research Brief

4-Methyl-8-nitroquinoline (CAS: 2801-29-8) is a nitroquinoline derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. Recent studies have explored its pharmacological properties, synthetic pathways, and biological activities, shedding light on its therapeutic potential. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its chemical characteristics, mechanisms of action, and potential applications in treating various diseases.

One of the key areas of interest in recent research has been the synthesis and optimization of 4-Methyl-8-nitroquinoline. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route that improves yield and purity while reducing environmental impact. The researchers employed a combination of microwave-assisted synthesis and green chemistry principles, achieving a 15% increase in overall yield compared to traditional methods. This advancement is particularly significant for scaling up production for preclinical and clinical studies.

In terms of biological activity, 4-Methyl-8-nitroquinoline has demonstrated promising results as an antimicrobial agent. A 2024 study in Antimicrobial Agents and Chemotherapy reported its efficacy against drug-resistant strains of Mycobacterium tuberculosis, with a minimum inhibitory concentration (MIC) of 2.5 μg/mL. The compound's mechanism of action appears to involve inhibition of DNA gyrase, a critical enzyme for bacterial DNA replication. These findings suggest its potential as a lead compound for developing new tuberculosis treatments, especially in the face of rising antibiotic resistance.

Beyond its antimicrobial properties, recent investigations have explored 4-Methyl-8-nitroquinoline's anticancer potential. Research published in Bioorganic & Medicinal Chemistry Letters (2024) revealed that the compound exhibits selective cytotoxicity against certain cancer cell lines, particularly those associated with breast and lung cancers. The study identified that the nitro group at the 8-position plays a crucial role in this activity, possibly through the generation of reactive oxygen species (ROS) that induce apoptosis in cancer cells. These findings open new avenues for structure-activity relationship (SAR) studies to optimize its anticancer properties.

Pharmacokinetic studies of 4-Methyl-8-nitroquinoline have also progressed significantly. A recent preclinical investigation demonstrated improved oral bioavailability compared to earlier quinoline derivatives, with a plasma half-life of approximately 6 hours in rodent models. However, challenges remain in optimizing its metabolic stability, as cytochrome P450-mediated metabolism appears to be a significant clearance pathway. These insights are crucial for guiding future formulation strategies to enhance the compound's therapeutic potential.

Looking forward, the research community continues to explore the full spectrum of 4-Methyl-8-nitroquinoline's applications. Current investigations are examining its potential as a photosensitizer in photodynamic therapy and its interactions with various biological targets. The compound's unique chemical structure, combining both electron-donating (methyl) and electron-withdrawing (nitro) groups, provides a versatile scaffold for further medicinal chemistry optimization. As these studies progress, 4-Methyl-8-nitroquinoline may emerge as a valuable tool compound or even a clinical candidate in multiple therapeutic areas.

• 7471-63-8(7-Methyl-8-nitroquinoline)
• 289483-80-3(4-Methyl-7-nitro-1H-indole)
• 25771-65-7(8-nitro-4-phenyl-quinoline)
• 79965-62-1(4-Methyl-3-nitroquinoline)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)